FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.200,54 +1.510,26 (+2,57%)
Basilea Pharmaceutica AG (0QNA.L)
| Chiusura precedente | 41,95 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 40,75 - 41,95 |
| Intervallo di 52 settimane | 32,20 - 51,30 |
| Volume | |
| Media Volume | 4.885 |
| Capitalizzazione | 4,397M |
| Beta (5 anni mensile) | 0,58 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,58 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 02, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal inf
- GlobeNewswire
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one of the world's leading peer-reviewed medical journals.1 In the study, Basilea’s ceftobiprole, a beta-lactam antibiotic, was evaluated for
- GlobeNewswire
Basilea reports strong revenue and profit growth in first half-year 2023
Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9 million and net profit to CHF 31.9 millionIncrease in cash and restricted cash to CHF 112.9 millionFull-year 2023 revenue and profit guidance increased Submitted US NDA for ceftobiprole in August Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 15, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical co
